AKT1 and glioblastoma: Moreover, GBM cells often exhibit adaptive resistance through the upregulation of alternative oncogenic pathways, including STAT3, PI3K/AKT/mTOR, and MAPK signaling, which can functionally compensate for NF-κB inhibition and maintain tumor survival and proliferation [130,131,132].